Risk factor
Meaningful price volatility
Profitability factor
Favourable price performance
About
Orchid Pharma Limited is a pharmaceutical enterprise primarily focused on the creation, production, and distribution of various pharmaceutical goods within India. Its offerings include active pharmaceutical ingredients (APIs), bulk pharmaceutical materials, finished dosage forms, and nutraceuticals. The company's comprehensive API portfolio features both oral and injectable cephalosporins, alongside specialized products for human and animal health. Additionally, their antibiotic selection encompasses betalactam, macrolide, fluoroquinolone, and imidazole compounds. Beyond its domestic activities, Orchid Pharma Limited also engages in international commerce, exporting its products to approximately 40 countries globally. Established in 1992, the company maintains its corporate headquarters in Chennai, India. It officially adopted its current name, Orchid Pharma Limited, in October 2015, having previously been known as Orchid Chemicals & Pharmaceuticals Limited. Currently, it operates as a subsidiary under Dhanuka Laboratories Limited.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB
Target Price
The average target price of ORCHPHARMA.NS is 928 and suggests 12.8% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recom